Bowman-Birk inhibitors (BBIs) are protein molecules containing two inhibitory domains for enzymes similar to trypsin and chymotrypsin. Interest in these inhibitors arose from their properties against the cancer chemically induced by 1,2-dimethylhydrazine (DMH). In this study the effect of two BBI preparations (from Glycine max and Macrotyloma axillare) were evaluated for the prevention of colorectal neoplasia induced by intraperitoneal injections of DMH, given at a dose of 30 mg/kg, during 12 weeks. Mice treated with DMH presented histopathological alterations consistent with tumor development, augmented CD44 expression and increased proteasome peptidase activities. Lysosomal fractions, obtained from the intestines, were chromatographed in a Sepharose-BBI column and increased activity for trypsin and chymotrypsin-like proteases recovered from DMH-treated animals. In parallel, mice treated for eight weeks with BBIs showed a decrease in the chymotrypsin and trypsin-like proteasome activities compared to animals fed on normal diet. For the groups receiving simultaneous treatment with DMH and BBIs, dysplasic lesions were not observed and proteasome peptidase activities were similar to the control group after the 24th week. These results suggest that the mechanism by which BBIs could prevent the appearance of pre neoplastic lesions is associated with inhibition of both the lysosomal and proteasome-dependent proteolytic pathways.
Introduction
Advances in industrialization generate an increasing frequency of exposure to new chemicals that are potentially harmful to cells and hence capable of inducing cancer. Active substances known to be important for the prevention of colorectal cancer are present in a variety of plants (Forman et al., 2004) . In this regard, soybean has been considered an important food source containing chemopreventive compounds (Losso, 2008) . Earlier studies indicated the Bowman-Birk inhibitor (BBI/M r $ 8 kDa) which contains two distinct inhibitory domains for enzymes similar to trypsin and chymotrypsin as the main soy component endowed with anticancer activity (Deshimaru et al., 2004; Odani and Ikenaka, 1973) . In particular, the antichymotrypsin inhibitory activity of BBIs has been correlated to their anticarcinogenic activity (Kennedy et al., 2008) . Nevertheless, it has been demonstrated that other soy constituents are known to contribute to this effect such as lunasin and a variety of small organic components (Gomes et al., 2005; Hernandez-Ledesma et al., 2009; Kris-Etherton et al., 2002) .
The 20/26S proteasome complex is currently considered an important intracellular target for antitumor drugs (Montagut et al., 2006) . Although the proteasome is classified as a threonine protease, its proteolytic core contains catalytic subunits exhibiting caspase (b1), trypsin (b2) and chymotrypsin (b5)-like activities (Tanaka, 2009) . Bortezomib is the first proteasome inhibitor approved by the FDA (Food and Drug Administration), known to be effective in some hematological malignancies for treatment of 0278-6915/$ -see front matter Ó 2012 Elsevier Ltd. All rights reserved. doi:10.1016/j.fct.2012.01.036
Abbreviations: BBIs, Bowman-Birk inhibitors; DMH, N,N 0 -dimethylhydrazine; MCA, 7-amide-4-methylcoumarin. multiple myeloma (Cavo, 2006; Chen et al., 2011) . It was demonstrated that the use of proteasome inhibitors results in multiple cellular effects, including promotion of anti-inflammatory, anticarcinogenic, anti-proliferative and apoptotic effects in cells exhibiting abnormal development (Mitsiades et al., 2002; Myung et al., 2001) . Other studies demonstrated that BBIs specifically inhibited the chymotrypsin-like proteasomal activity in MCF7 tumor cells causing accumulation of ubiquitinated substrates and a decrease in the levels of regulatory cyclins (Chen et al., 2005) .
The present study refers to an evaluation of the protective effects of BBIs isolated from Glycine max and Macrotyloma axillare during development of colorectal tumors caused by administration of the carcinogen 1,2-dimethylhydrazine to mice. In addition to display trypsin and chymotrypsin inhibitory properties M. axillare BBIs share relevant primary and 3D structural features with soybean BBI, such as the conserved cysteine residues involved in disulfide bond formation (Kumar et al., 2002) . However, specific differences observed in amino acid composition may account for some particular pharmacokinetic properties of M. axillare BBIs, including a higher distribution to stomach (Santana et al., 2011) , most likely due to a higher interaction followed by enhanced internalization in the gastric tissue. In the present study the protective effects of these two BBI preparations were assessed through histopathological examinations, evaluation of the proteasome peptidase activities, CD44 protein expression by Western blotting and evaluation of the enzyme activities retained in a Sepharose-BBI affinity column.
Materials and methods

Ethics statement, experimental animals and reagents
Swiss male mice aged 120 days were obtained from the Center for Animal Science, Universidade Federal de Ouro Preto. All procedures involving animals were carried out in accordance with the national guidelines provided by the local ethics committee. The animals were maintained under a light/dark cycle of 12 h and given food and water ad libitum. N,N 0 -Dimethylhydrazine (DMH) 99% and fluorogenic substrates Boc-Val-Pro-Arg-MCA (amide-4-methylcoumarin) and Suc-Ala-Ala-Pro-Phe-MCA were from Sigma (Sigma-Aldrich, St. Louis, USA). Purified anti-mouse CD44 was purchased from BD Biosciences Pharmingen™ (BD Biosciences PharMingen, New Jersey, USA). The fluorogenic substrates, Cbz-Gly-Gly-Arg-MCA and Suc-LeuLeu-Val-Tyr-MCA were purchased from Biomol International (Biomol, Exeter, UK).
Experimental groups
The group of animals named BBIS received a diet supplemented with 0.1% w/w enriched soybean (G. max) BBI, produced according to methods previously described (Yavelow et al., 1985) . BBIM group refers to animals treated with a preparation of enriched BBIs from the leguminous M. axillare, produced according to our patented isolation protocol available at http://www.patentesonline.com.br/processo-de-preparacao-de-extrato-ativado-de-bowman-birk-de-macrotyloma-axillare-115536.html. In the last case, the dose added to the diet showed antitrypsin activity equivalent to that contained in 0.1% w/w soybean BBI. The homogeneity of the two BBI preparations was assessed using 15% SDS-PAGE. For the induction pre neoplastic lesions and neoplasia, mice were subjected to intraperitoneal injections of DMH weekly, at a dose of 30 mg/kg in citrate buffer/EDTA (1 mM EDTA, 10 mM sodium citrate, 0.9% NaCl, pH 8.0) during 12 weeks. Injection volume was 150 lL. Animals were maintained for a latency period of 12 additional weeks.
Overall, mice were divided into six treatment groups (n = 18 animals/group) as follows -Control group (citrate/EDTA), DMH group (DMH), DMHS group (DMH and diet supplemented with BBI from G. max) and DMHM group (DMH and diet supplemented with BBI from M. axillare). Two additional control groups were given a diet supplemented with either 0.1% G. max BBI (BBIS) or M. axillare BBIs (BBIM) for 8 weeks.
Histopathological analyses
Representative animals of the various treatment groups had their colon and intestine removed during necropsy for histopathological analyses. The organs were fixed in buffered formalin and embedded in paraffin. Histological sections of 5 lm were obtained using a microtome. These were fixed on slides followed by staining with a Hematoxylin Eosin preparation. Qualitatively evaluated parameters were: presence/absence of atypical cells either present in the mucous, middle or serosa layer; mucosa inflammation; necrosis; atypical structures and hyperplasia of the lymphoid nodules.
2.4. In gel proteolytic digestion and peptidase activities of the fraction purified from a Sepharose-BBI column Protein samples from the small intestine and colon of each experimental group were subjected to affinity chromatography using a Sepharose column containing immobilized M. axillare BBI. Coupling of purified M. axillare BBI to the Sepharose matrix was performed as previously described (Matsumoto et al., 1981) . Homogenates obtained from 100 mg of colon and intestine tissues were prepared in PBS pH 7.4 containing 1 mM MgCl 2 using a Branson 250 sonifier. After centrifugation at 1000g for 10 min, to eliminate cell/tissue debris, the supernatant was removed and recentrifuged at 10,000g for 20 min to obtain a soluble and a pellet fraction. Lysosomes were further enriched from the pellet fraction following the protocol as described elsewhere (Billings et al., 1988) . The lysosome-enriched pellet fraction was resuspended in 50 mM phosphate buffer pH 7.0 containing 1 mM MgCl 2 and 0.1% Triton X-100. Lysosomal proteins were extracted by five cycles of sonication for 30 s with 1 min intervals on ice. After centrifugation at 10,000g for 5 min, the supernatant containing lysosomal proteins was obtained. The lysosomal and soluble fractions were separately loaded onto the Sepharose-BBI column. The column was extensively washed with 50 mM Tris-HCl pH 7.0, 1 mM MgCl 2 , 500 mM NaCl and the bound fraction obtained by decreasing the pH to 1 using 100 mM HCl. Proteolytic activity present in this fraction was demonstrated by 12% PAGE with the gel matrix containing 0.1% gelatin as described by (Billings et al., 1991) . In parallel, peptidase activities related to trypsin and chymotrypsin were evaluated by hydrolysis of the fluorogenic substrates Boc-Val-Pro-Arg-MCA and Suc-Ala-Ala-Pro-Phe-MCA, respectively. The assays were conducted using an aliquot of 40 lL of each fraction and 1.6 mM of the substrates in a final volume of 240 lL. The hydrolysis reaction occurred for 30 min at 37°C and stopped by addition of 3 mL 50 mM sodium phosphate, pH 8.0. Fluorometric readings were obtained at the wavelengths of 380 nm (excitation) and 460 nm (emission) using the RF-5301PC fluorometer (Shimadzu, Japan). Results were expressed as fluorescence arbitrary units/lg protein applied to the column.
Assessment of proteasome peptidase activities
Approximately 100 mg of the small intestine and colon of animals from the different experimental groups were homogenized in 3 mL of 20S buffer (25 mM TrisHCl pH 7.5, 1 mM DTT, 10% glycerol). Protein extraction was first performed using a tissue homogenizer (Potter Elvejhem) followed by sonication under three cycles of 40 and 15 s intervals in an ice bath. Samples were centrifuged for 30 min at 10,000g and the supernatant submitted to ultracentrifugation for 6 h at 100,000g. One mL fractions taken from the bottom of the tubes were used to assess the proteasome's trypsin-and chymotrypsin-like peptidase activities, using the respective fluorogenic substrates Cbz-Gly-Gly-Arg-7-amide-4-methylcoumarin and Suc-LeuLeu-Val-Tyr-7-amide-4-methylcoumarin. The reactions were performed using 15 lg total protein and 13 lM of fluorogenic substrates for a final volume of 240 lL, in 50 mM Tris-HCl pH 8.0 containing 10 mM MgCl 2 . The chymotrypsin-like assay was also performed in the presence of 20 lM MG132, a proteasome inhibitor, to control for proteasome-specific activity. Fluorometric readings were performed at wavelengths of 380 nm (excitation) and 460 nm (emission), and results expressed as fluorescence arbitrary units/lg protein.
Analysis of CD44 expression by Western blotting
Approximately 100 mg of the colon of animals from the different experimental groups were used for preparing protein extracts in 1 mL of 50 mM Tris-HCl pH 7.5, 1 mM DTT, 10% glycerol in the presence of 1Â PIC (Protease Inhibitor Cocktail, Sigma) through sonication, as described in Section 2.5. The protein homogenate was then centrifuged at 10,000g for 20 min and the supernatant stored at À80°C. One millilitre of a buffered solution (100 mM Tris-HCl, pH 7.5, 0.1% SDS, 1% Triton X-100) was used to resuspend the remaining pellet. The membrane suspension was extracted by agitation through vortexing, the preparation boiled for 5 min and centrifuged at 10,000g for 10 min. The integrity of the proteins extracted from the membrane fractions was assessed using 12% SDS-PAGE and the protein content estimated by densitometric analysis. Fifteen micrograms of each of the fractions were then separated using 12% SDS-PAGE and immediately transferred to a PVDF membrane essentially as described by (Towbin et al., 1979) . After a blocking step of the membrane in TBST (50 mM Tris-HCl pH 8.3, 150 mM NaCl, 0.05% Tween-20) containing 5% non-fat milk for 12 h, the membrane was incubated with the rat anti-mouse CD44 monoclonal antibody at a dilution of 1:1000, in the same buffer. Incubation was performed for 3 h at room temperature. Visualization of the CD44 protein isoforms was possible after incubation of the membrane with alkaline phosphatase-labelled anti rat IgG antibody in TBST/milk for 1.5 h, followed by addition of the enzyme substrates nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate, used according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was performed by means of the Prism software, using analysis of variance between groups (ANOVA), which guarantees normal distribution of data and the complementary Tukey's test, considering a significance level of p 6 0.05.
Results
3.1. BBIs from M. axillare and G. max protect against the development of pre neoplastic lesions induced by DMH The percentage of animals that presented macroscopic and microscopic alterations in the colon and small intestine from the different experimental groups is indicated in Table 1 . It was observed that 45% of the mice that received DMH presented macroscopic alterations in the colon and small intestine. With respect to microscopic alterations, dysplastic and neoplastic lesions were observed in 56% and 33% of the colon and small intestine, respectively, only in animals under DMH-treatment. Fig. 1A shows a macroscopic lesion corresponding to a polyp formation in the colon of DMH-treated animals. These were found distributed throughout the intestine. Fig. 1B reveals the histologic aspects of the polipomatous lesion and its insertion in the mucosa, squared area. Fig. 1D demonstrates architectural details of the proliferative lesion from DMH-treated animals and its associated-inflammatory response. No tissue alterations were found for animals in the remaining groups (DMHS and DMHM), attesting for the protective effect of diet supplementation with BBIs. At the employed dosage regimen BBI from the two sources were equally effective for the prevention of pre neoplastic lesions with no significant differences in the parameters used to evaluate the small intestine and colon. Nevertheless, specific inhibitory activity assays comparing the properties of the main BBI isoforms present in these two preparations and isolated according to (César et al., 2009 ) revealed BBI from M. axillare being 33% and 69% more active against bovine trypsin and chymotrypsin, respectively, compared to G. max BBI -Supplementary Table 1. It's worth emphasizing that a severe inflammatory response was observed in the colon and small intestine of animals in the DMH-treated group. A representative result from the colon is presented in Fig. 2 showing the inflammatory infiltrate in the muscle layer in animals of the DMH group (Fig. 2B ) and the absence of such response in animals from DMHS and DMHM groups (Figs. 2C and D) . Altogether these results revealed the protective effects of our two BBI preparations for DMH-induced inflammation and development of pre neoplastic lesions.
DMH-treatment induces increase in trypsin-and chymotrypsinlike activities in the lysosomal fraction
Lysosomal fractions from intestine and colon of the various animal groups were used to evaluate their ability to hydrolyze fluorogenic substrates to trypsin and chymotrypsin-like enzymes, after the 24th week of experimentation. Prior to the enzymatic assays, the lysosomal fractions were submitted to affinity chromatography using a Sepharose-BBI column, to recover proteolytic activity related to trypsin and chymotrypsin enzymes. Fig. 3 reveals that both activities are increased in the intestine and colon of animals from the DMH group. The low trypsin-and chymotrypsin-like activities in the lysosomal fractions derived from the control group allowed us to establish a correlation between the increase in proteolytic activity and the presence of neoplastic lesions. Animals from DMHS and DMHM groups exhibited proteolytic activities similar to the untreated control group.
CD44 protein expression increases in neoplastic lesions from DMH-treated animals
Total membrane fractions were obtained from the small intestines of control and DMH-treated groups for evaluation of CD44 expression levels by Western blotting. Protein samples from three representative animals in each group were separated by SDS-PAGE and the gel image used for quantification of total protein loading. Densitometric analysis revealed no significant difference between the amounts of protein transferred to the PVDF membrane comparing control and DMH-treated animals. When the membrane was immunoblotted with anti-CD44, it was clearly observed increased levels of CD44 expression in the fractions corresponding to membrane extracts from the intestinal polyps induced by treatment with DMH, Fig. 4A . The appearance of CD44 positive bands unique to DMH-treated animals is also indicated by arrows. Fig. 4B corresponds to the densitometric analysis of the blotted membrane shown in Fig. 4A . Diet supplementation with both BBI preparations revealed no significant difference in the expression pattern of CD44, compared to control groups (data not shown). This result provided molecular evidence for the development of pre neoplastic lesions induced by DMH.
Treatment with BBIs inhibits the proteasome's chymotrypsin and trypsin-like activities
Treatment with either 0.1% w/w G. max BBI or M. axillare BBIs (the latter given at a dose equivalent to the inhibitory activity present on 0.1% G.max BBI) added to the animal diet for 8 weeks promoted decrease in the chymotrypsin-and trypsin-like activities of the proteasome extracted from the colon. The assays revealed a reduction of approximately 50% in both activities for animals treated with both BBI preparations, Fig. 5 . Apparently BBI from soybean seem to be more effective at inhibiting both the trypsin and chymotrypsin-like proteasome activities but the observed differences were not statistically significant. In addition, aiming to evaluate the proteasome activities from mice simultaneously treated with these inhibitors plus DMH, colon protein extracts from the various groups were subjected to proteasome's activity assays. The results presented in Fig. 6 clearly show a remarkable increase in the trypsin-and chymotrypsin-like activities of the proteasome for the DMH group. Proteasome peptidase activities were similar to the control for DMHS and DMHM groups. Use of MG132, a classical proteasome b5 subunit inhibitor, revealed approximately 80% reduction in the chymotrypsin-like activity; meaning this enzyme activity was major attributed to proteasome function, Fig. 6 . Table 1 Percentage and number of animals that presented macroscopic and microscopic alterations in the colon and small intestine from the different experimental groups.
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Discussion
Considering that pre neoplastic lesions precede malignant transformation our study confirms previous results demonstrating the ability of soybean BBIs to inhibit carcinogenesis induced by DMH, (Kennedy, 1998; Kennedy et al., 1996; Kennedy et al., 2002) . Experiments aimed at elucidating the mechanism of action of BBIs, as cancer preventive agents, showed an increased expression of proteolytic enzymes exhibiting trypsin-and chymotrypsin-like activities. These could be recovered from the lysosomal fraction after affinity chromatography on a Sepharose-BBI column St Clair et al., 1990) . Therefore, the cell molecular targets of BBIs have been primarily centered on lysosomal proteases. Despite their unknown nature, zymogram analyses and peptidase activities demonstrated that BBI protease ligands were in the mass range of 45-66 kDa, as determined by SDS-PAGE. More recently, it was demonstrated that purified soybean BBIs inhibited the 20S proteasome's chymotrypsin-like in breast cancer cells (Chen et al., 2005) . Reinforcing the proteasome's inhibition by BBIs, it was reported reduced degradation of ubiquitinated connexin 43 in tumor cells treated with BBIs, leading to enhanced cell adhesion (Saito et al., 2007) . In addition, specific inhibitors of the proteasome's chymotrypsin-like activity have been shown to induce apoptosis of cancer cells and suppress tumor growth in several experimental models (Chen et al., 2005; Kisselev et al., 2006) .
Until now, few studies have demonstrated the use of BBIs as potential inhibitors of proteasome activity. The present data reveals for the first time the in vivo effects of two BBI preparations, given as a diet supplement to healthy animals, upon proteasome capabilities. The eight week's treatment with either G. max BBI or M. axillare BBIs incorporated in the diet, resulted in a decrease of approximately 50% in the trypsin-and chymotrypsin-like activities of the proteasome isolated from the colon of mice. This in vivo effect is consistent with both a considerable absorption of these inhibitors given orally, reaching 50% bioavailability (Billings et al., 1991) and the need for cellular internalization of BBI to gain access to their potential targets (Chen et al., 2005) . No histopathologic alterations were observed in the small intestine and colon from animals receiving a diet supplemented with BBI from the two sources. Furthermore, the protective effects of these two BBI preparations were correlated with maintenance of normal proteasome-dependent proteolytic activity, during simultaneous treatment with DMH. Altogether, our results provide evidence for the suppressive effect of BBIs being correlated with inhibition of at least two intracellular proteolytic systems: the lysosomal and the proteasome-dependent pathway.
Histopathological analyses attested for the protective effect of BBIs based on the absence of tissue alterations indicative of tumor development. At the molecular level, control levels of CD44 protein expression was observed in DMHS and DMHM groups, as opposed to the clearly increased levels of CD44 isoforms in the colon induced solely by DMH-treatment. It is important to emphasize that increased CD44 protein expression and particularly the appearance of aberrant CD44 isoforms, due to alternative splicing, is a hallmark of the cell proteome associated to the development of colon tumors (Hynes et al., 2009 ). Moreover, considering that CD44 are proteoglycans their molecular diversity is also explained by differentially attached glycans, adding complexity to their electrophoretic pattern (Arcinas et al., 2009 ). Particularly, as our primary antibody does not discriminate among CD44 isoforms we believe, judged by the electrophoretic pattern, we have detected the standard CD44 (CD44s) at approx. 80 kDa and high molecular mass CD44 molecules, which should account for other CD44 splice variants (Brown et al., 2011; Godge and Poonja, 2011; Hanley et al., 2006) . In addition to the appearance of high mass CD44 positive bands, unique to the DMH-treated group, we have also observed a marked increase in the amount of detected CD44 at the mass range 25-30 kDa. As this mass range is not compatible with the full length CD44, we hypothesized that it corresponds to CD44 cleavage products previously shown to accumulate at the neoplastic tissue and known to contribute to tumor progression in various animal cell lines (Sugahara et al., 2008; Wang et al., 2009 ). The use of two BBI preparations aimed the comparison of their tumor-preventive activities. The dose to be incorporated in the diet was standardized based on their inhibitory activity over bovine trypsin. The results revealed that both preparations were equally effective at preventing the appearance of tissue biomarkers associated with tumor development. Nevertheless, a comparative analysis of the primary sequences of BBIs isolated from G. max and M. axillare, in particular at the regions corresponding to their inhibitory heads, permitted observation of critical amino acid differences. In this regard, the active sequences of G. max BBI are CTKSNPPQC and CALSYPAQC for the inhibitory heads of trypsin and chymotrypsin, respectively. M. axillare BBIs are composed of two types of molecules named DE3 and DE4, displaying identical amino acid sequences for the trypsin-inhibitory head (CTKSIPPQC) and distinct sequences (CTFSIPAQC and CALSEPAQC) for the chymotrypsininhibitory head, respectively, (Joubert et al., 1979) . Given that the amino acid found in the P2' position of M. axillare native BBI inhibitor is Ile and the best observed modification in P2 0 position of a cyclic synthetic peptide was found to be associated with the same amino acid, resulting in a change of K i from 2.5 to 0.009 lM (Gariani et al., 1999) , we suggest that M. axillare BBIs and/or their byproducts generated once given orally, have the potential to act as potent protease inhibitors. This argument is strengthened considering that during germination of M. axillare there is proteolytic processing of the native inhibitor, giving rise to short molecules known to be 5 times more potent than the full length inhibitor found in dormant seeds (Kumar et al., 2002) . In addition, as for the chymotrypsin inhibitory head, particularly between the P2 e P2 0 positions, significant amino acid differences in DE3 and DE4 isoforms exist compared to the respective sequence found in soybean BBI. Altogether, these findings provided our rationale for proposing the utilization of an alternative BBI source (M. axillare BBI) to prevent DMH-induced lesions.
Given the structural differences and the potential therapeutic role of BBIs, detailed investigations are necessary for elucidating the structure/activity relationship of such inhibitors. This would allow exploration of their activity upon intracellular protein turnover, either mediated by the lysosome or the 20S/26S Fig. 4 . CD44 expression pattern in the colon from control and DMH-treated animals. (A) Extracted membrane proteins from the colon of three control and three DMH-treated animals were separated using 12% SDS-PAGE, transferred to a PVDF membrane and immunoblotted using an anti-CD44 antibody. Note the increased expression of CD44s in DMH-treated animals and the appearance of high mass CD44 isoforms unique to this group (arrowed). Detection of CD44 cleavage products at the mass range 25-30 kDa was also particularly prominent in the DMH group (arrowed). (B) Densitometric analysis of the blotted membrane shown in (A). Significantly different values were observed from the control using ANOVA/Tukey's test at p 6 0.05. Fig. 5 . Animals fed a diet containing either G. max BBI (BBIS) or M. axillare BBIs (BBIM) during 8 weeks displayed decreased proteasome activity. Proteasome's trypsin (T) and chymotrypsin (Q)-like activities were assayed for control and BBIS/ BBIM groups. Q-like activity was also performed in the presence of MG132 to control for proteasome's specific activity. Assays were performed using samples from six animals in each treatment group and the results were expressed as means through fluorescence arbitrary units/lg protein. Bars represent the standard errors of the means. Values significantly different from the control were observed at p 6 0.05 using ANOVA/Tukey' test. Fig. 6 . DMH-treatment induces increase in the colon proteasome's trypsin-and chymotrypsin-like activities whereas DMH plus BBIs keep them equivalent to control levels. Q-like activity was also performed in the presence of MG132 to control for proteasome's specific activity. Assays were performed using samples from six animals in each treatment group and the results were expressed as means through fluorescence arbitrary units/lg protein. Bars represent the standard errors of the means. Values significantly different from the control were observed at p 6 0.05 using ANOVA/Tukey' test.
proteasome, towards prevention of various diseases including cancer.
Conclusions
In our experiments mice simultaneously treated with DMH and either G.max or M. axillare seed BBIs, the induction of neoplastic lesions could be prevented. Since their effects correlated with their inhibitory potential over bovine trypsin and given the increased activity of M. axillare BBIs over this enzyme, we suggest that the latter inhibitors could be used in doses much lower than that required for soybean BBI. Histopathological analyses revealed that both BBI preparations protected against the onset of severe inflammatory processes and ultimately the appearance of pre-malignant lesions, observed in DMH-treated animals. The two investigated biomarkers (expression of CD44 and lysosomal protease activities associated with a BBI-affinity column) showed consistent results under the different experimental conditions, demonstrating their reliability and usefulness in this experimental model. Finally, this study demonstrated a significant increase in the trypsin and chymotrypsin-like activities of the proteasome in pre neoplastic lesions of the colon from DMH-treated animals. In contrast, normal levels were observed for proteasome activity found in animals treated simultaneously with BBIs and DMH.
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